TP53 and cholangiocarcinoma: A recent systemic review has suggested that p53 mutation, cyclins, proliferation indices (Ki-67), mucins, CA19-9, and CEA have potential as prognostic predictors in cholangiocarcinoma [38], however, there is no targeting therapy for these molecules at present.